Cannabis Law Report

JUNE 1, 2021

The initial shipment is designated to be used by the Clinic in a pilot run in preparation for the previously announced study , based out of the United Kingdom, on the safety and efficacy of cannabis and hemp for the treatment of patients suffering from chronic pain. About RYAH Group, Inc. RYAH Group, Inc.

Clinical Trials 89

Clinical Trials Chronic Pain Data Research and Development 89

The Joint Blog

APRIL 17, 2020

But as an older user-base with more complicated medical conditions continue to grow, it is important to understand how THC could adversely impact other co-administered medications. Medical cannabis is typically prescribed for patients with severe conditions including inflammatory conditions (e.g.,

Events 48

Events THC Chronic Pain Sleep 48

Cannabis Law Report

JUNE 16, 2021

This engagement will build on the strong foundation on Santé, having treated more than 10,000 patients since 2014 under a real-world data protocol. Training will be provided within the research program for licensed practitioners to assess the safety of psychedelic medicines and to classify and report positive and adverse events.

Clinical Trials 104

Clinical Trials Therapy Research and Development Events 104

Cannabis Law Report

AUGUST 27, 2021

The Board will advise Delic and its subsidiaries, including Ketamine Infusion Centers, Delic Labs and others, as they develop safety protocols and best practices pertaining to legal psychedelic wellness treatments today and those legalized in the future.

Research and Development 98

Research and Development Treatment Media Medicine 98

Veriheal

MAY 30, 2023

Cancer Pain Relief With Cannabis: What the New Study Shows Utilizing data from the Quebec Cannabis Registry in Canada, researchers sought to examine the safety and effectiveness of cannabis in addressing cancer pain. Always consult a physician before making any decision on the treatment of a medical condition.

Medicine 96

Medicine Treatment Patients Data 96

Cannabis Law Report

JULY 29, 2021

Our evidence-based scientific approach has enabled us to develop a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. Forward-looking statements. Some statements in this release may contain forward-looking information.

Research and Development 105

Research and Development Clinical Trials Events Cannabinoids 105

Cannabis Law Report

OCTOBER 22, 2021

–The Company expects to hold a Research & Development event to review,these breakthrough findings in Q4 2021 that will be open to the public, shareholders, analysts and the media– TORONTO, CANADA – October 19, 2021 – Cybin Inc.

Research and Development 52

Research and Development Safety Media Data 52

Cannabis Law Report

JUNE 16, 2021

Genetic Screening Platform Technology and Data to Strengthen Entheon’s Psychedelic-Assisted Protocols. Lobo brings a highly experienced and specialized team of technology experts in the fields of genetics, diagnostics, data and analytics, as well as a fully operational 5,000 sq. Vancouver, British Columbia–(Newsfile Corp.

Research and Development 105

Research and Development Data Conditions Events 105

Cannabis Law Report

AUGUST 17, 2021

(Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced topline data from its open-label Phase 2 trial evaluating safety and efficacy of adjunctive oral ganaxolone treatment in 23 patients with seizures associated with tuberous sclerosis complex (TSC).

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

OCTOBER 6, 2021

Flora Pharma will seek to identify scientific gaps in the cannabis industry and ultimately work to translate that to pharmaceutical cannabis products backed by data. Flora Pharma expects to fast track traditional FDA and NHS timelines by running phase trials in parallel (in vitro, in vivo, pilot in human, safety/efficacy, etc.).

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Events 52

Cannabis Law Report

FEBRUARY 9, 2022

These are the very first draft rules that we’re seeing, so it really is a kind of pivotal event.”. But this is the first time Oregonians have been allowed to see some of the nuts and bolts of what some predict could grow into a billion-dollar industry nationally, according to Data Bridge Market Research.

Clinical Trials 52

Clinical Trials Microdosing Safety Conditions 52

Cannabis Law Report

AUGUST 27, 2021

Closing of the Private Placement is subject to a number of conditions, including receipt of all necessary corporate and regulatory approvals, including approval of the Toronto Stock Exchange. Each whole Warrant will entitle the holder to acquire one additional Common Share at a price of USD$0.50 HempFusion Wellness Inc.

Research and Development 105

Research and Development Events Hemp Food 105

Cannabis Law Report

AUGUST 23, 2021

FDA has not reviewed the manufacturing process of these unapproved CBD-containing drug products, so the manufacturing conditions of, or contaminant levels in, these products is unknown. He added that significant data is still needed to inform policy regarding use of consumer cannabis products.

Pets 105

Pets Hemp CBD Food 105

Cannabis Law Report

MAY 19, 2022

FDA states it has serious safety concerns with delta-8 THC. FDA states it has received 104 reports of adverse events in patients who consumed delta-8 THC products between December 1, 2020 and February 28, 2022. FDA considers delta-8 THC to pose serious health and safety risks. FDA Warning Letters. meat, milk, and eggs).

THC 52

THC CBD Food Pets 52

Puff Puff Post

MARCH 10, 2020

” Study 755-101-HV is a randomized, vehicle controlled, double-blind, Phase 1 trial, examining the safety and tolerability of two strengths of INM-755 cream in 22 healthy adult volunteers over a 14-day treatment period as part of a randomized, vehicle controlled, double-blind, Phase 1 trial.

Clinical Trials 84

Clinical Trials Pharmaceutical Research and Development Cannabinoids 84

Cannabis Law Report

MAY 6, 2022

The FDA explains it is monitoring the selling of CBD and Delta-8 THC products out of a growing safety concern. In short, the FDA has not evaluated or logged all dangerous side effects or safety concerns. Pre-clinical data support the possible use of CBD with Panic Disorder…Bipolar Disorder.”. Taking CBD can relieve pain.”. “In

THC 52

THC CBD Media Food 52

The Cannigma

OCTOBER 21, 2021

Attention deficit hyperactivity disorder, or ADHD, is a condition characterized by behavioral symptoms such as inattentiveness, hyperactivity, impulsiveness. While there has been little systematic research on using cannabis for ADHD, many patients with the condition report positive effects from using cannabis. What is ADHD?

Blood Pressure 137

Blood Pressure Treatment Patients Cannabis 137

Cannabis Law Report

JUNE 7, 2021

1.526 were reduced as expected and consistent with other CDC-reported data on vaccine-induced antibody neutralization against these variants 1. Department of Agriculture (USDA) or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final or conditional approval from the U.S.

Clinical Trials 64

Clinical Trials Research and Development Therapy Supply Chain 64

Cannabis Law Report

JANUARY 23, 2022

Events like these afford us a glimpse into the future of research and medicine in this field. Seeing these results for the first time alongside qualitative data in the form of patient testimonies and images was an incredibly profound experience that is hard to replicate in a written format. Many variables impact the outcomes of GVHD.

Research and Development 52

Research and Development Wellness and Beauty Patients CBD 52

Cannabis Law Report

JUNE 1, 2021

.” 1 Unless otherwise indicated, market share data disclosed in this press release is calculated using the Company’s internal proprietary market share tool that utilizes point of sales data supplied by a third-party data provider, government agencies and our own retail store operations across the country.

Data 95

Data Vaping Supply Chain Business 95

Puff Puff Post

MARCH 10, 2020

” Study 755-101-HV is a randomized, vehicle controlled, double-blind, Phase 1 trial, examining the safety and tolerability of two strengths of INM-755 cream in 22 healthy adult volunteers over a 14-day treatment period as part of a randomized, vehicle controlled, double-blind, Phase 1 trial.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

Cannabis Law Report

NOVEMBER 16, 2021

Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. Recruitment for the Phase 2 trial will begin immediately, and efficacy data is expected by the end of first quarter of 2022. “To BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. MyMD Contact: Robert Schatz.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

CannaMD

DECEMBER 9, 2020

The authors also list a range of additional conditions for which there are possible benefits of cannabis therapies, including opiate withdraw, dystonia, glaucoma, Alzheimer’s disease, anxiety and depression, anti-tumor effects, inflammatory bowel diseases, Parkinson’s disease, and sleep disorders. ACUTE EFFECTS OF MARIJUANA.

Marijuana 111

Marijuana Research and Development Consumption Vaping 111

CannaMD

SEPTEMBER 15, 2020

SHORT ANSWER: Full-time and seasonal Florida residents who suffer from an eligible medical condition. To qualify for medical marijuana in Florida, a patient must: Be diagnosed by a certified physician with a qualifying condition. Regular cannabis does not have to meet the same requirements. Who is eligible for medical marijuana?

Law 126

Law Marijuana Patients Treatment 126

SpeedWeed

JULY 30, 2021

In my review of that book for Leafly , I charged Berenson with being a fundamentally dishonest writer, willing to purposefully and consistently distort data and provide false witness so long as it bolsters his central claim that cannabis is incredibly dangerous. So if you’re asking me where to turn for the hard data, I’d say start here.

Marijuana 52

Marijuana History Data Strains 52

TheAnswerPage

JANUARY 11, 2022

As a result, state medical marijuana rules and regulations have focused on the demands of the public without putting significant emphasis on the scientific data or the ability of the medical community to support and care for medical marijuana patients.

Patients 98

Patients Education Marijuana Therapy 98

Cannabis Law Report

NOVEMBER 9, 2021

Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law. About LineaRx, Inc., For Applied DNA: Investor Contact: Sanjay M.

Clinical Trials 52

Clinical Trials Research and Development Therapy Supply Chain 52

Cannabis Law Report

SEPTEMBER 24, 2019

Epidyolex has been approved as a treatment option for children as young as two with Lennox-Gastaut syndrome or Dravet syndrome – difficult-to-treat conditions that can cause multiple seizures a day. The medication, developed by GW Pharmaceuticals, will be used in combination with another epilepsy medication called clobazam.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Cannabis Law Report

OCTOBER 26, 2021

an organization that provides support to pharmaceutical and biotech companies in North America, Europe, Japan, India and Africa on issues such as product safety, pharmacovigilance, medical devices, clinical trials and regulatory issues. 1 Data published by Research and Markets, March 2018. MyMD: Robert Schatz. 646) 421-9523.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

SpeedWeed

APRIL 28, 2021

Curaleaf also hosts panel discussions and support events for all team members: . The finalized contract guarantees a living wage, comprehensive benefits, opportunities for career advancement and safe working conditions for OSCC employees, according to a Local 328 press release. PRIDE/QUSH (Queer-Centered Unity and Service Huddle).

Seed-To-Sale 52

Seed-To-Sale Dispensary Cultivation Food 52

SpeedWeed

APRIL 28, 2021

Curaleaf also hosts panel discussions and support events for all team members: . The finalized contract guarantees a living wage, comprehensive benefits, opportunities for career advancement and safe working conditions for OSCC employees, according to a Local 328 press release. PRIDE/QUSH (Queer-Centered Unity and Service Huddle).

Legalization 52

Legalization Seed-To-Sale Dispensary Cannabis 52

SpeedWeed

APRIL 27, 2021

Curaleaf also hosts panel discussions and support events for all team members: . The finalized contract guarantees a living wage, comprehensive benefits, opportunities for career advancement and safe working conditions for OSCC employees, according to a Local 328 press release. PRIDE/QUSH (Queer-Centered Unity and Service Huddle).

Seed-To-Sale 52

Seed-To-Sale Dispensary Cannabis Cultivation 52

Project CBD

FEBRUARY 28, 2023

HerbalGram, the acclaimed quarterly journal of the American Botanical Council, recently published its 2021 “Herb Market Report,” which included data on sales of CBD as an herbal ingredient in mainstream and natural retail channels in the United States. Consumers spent roughly $31.3 increase in annual sales. Accessed July 25, 2021.

CBD 144

CBD Seed-To-Sale Food Access 144

SpeedWeed

APRIL 29, 2021

Curaleaf also hosts panel discussions and support events for all team members: . The finalized contract guarantees a living wage, comprehensive benefits, opportunities for career advancement and safe working conditions for OSCC employees, according to a Local 328 press release. PRIDE/QUSH (Queer-Centered Unity and Service Huddle).

Programs 52

Programs Seed-To-Sale Dispensary Cultivation 52

Cannabis Law Report

AUGUST 6, 2021

1 Unless otherwise indicated, market share data disclosed in this press release is calculated using the Company’s internal proprietary market share tool that utilizes point of sales data supplied by a third-party data provider, government agencies and our own retail store operations across the country. hemp industry in the U.S.,

Vaping 105

Vaping Research and Development Data Business 105

Cannabis Law Report

JULY 28, 2021

The study was conducted by a respected contract research organization with deep expertise in preclinical oncology model development and drug testing and data corresponding to all studied cancer cell lines have now been reported to the Company. ” Next Steps.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Cannabis Law Report

OCTOBER 26, 2019

Sponsors must also ensure compliance with the relevant guidelines as to good clinical practice and safety monitoring and reporting, and ensure that the use of personal information complies with the Privacy Act 1988. The TGA does not evaluate any data relating to the trial.

Clinical Trials 45

Clinical Trials Medicine Research and Development Compliance 45